PRODUCT LITERATURE

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

---

Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in
routine practice merits attention

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Clopidogrel
Acute Coronary Syndrome
Briclot
Ticagrelor

Specific Detail Info

JAMA. 2020;324(16):1640-1650

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment